Elevance Health Inc.
06/10/2026 | Press release | Distributed by Public on 06/10/2026 04:03
Regulation FD Disclosure (Form 8-K)
Item 7.01 - Regulation FD Disclosure
Officers of Elevance Health, Inc. (the "Company") expect to speak with investors and analysts this week. During these meetings, Company officers will reaffirm the Company's shareholders' earnings guidance for full year 2026 to be at least $19.85 per diluted share, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the Company continues to expect adjusted shareholders' earnings to be at least $26.75 per diluted share. This does not include any other adjustment items beyond those reported in the Company's first quarter 2026 earnings.
During these meetings, Company officers will also reaffirm full year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.
None of the information furnished in Item 7.01 hereto shall be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly set forth by specific reference in such filings, none of the information furnished in this report shall be incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings.
Elevance Health Inc. published this content on June 10, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 10, 2026 at 10:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]